1Costa LG,Cole TB,Furlong CE.Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates[J].J Toxicol Clin Toxicol,2003,41(1):37-45. 被引量：1
2Mackness B,Durrington P,McElduff P,et al.Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study[J].Circulation,2003,107(22):2775-9. 被引量：1
6Simon B C,Cunningham L D,Cohen R A,et al.Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery[J].J Clin Invest,1990,86(1):75-9. 被引量：1
7Furlong C E.PON1 status and neurologic symptom complexes in Gurf war veterans[J].Genome Res,2000,10(2):153-5. 被引量：1
8Rozenberg O,Rosenblat M,Coleman R,et al.Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress:studies in PON1-knockout mice[J].Free Radic Biol Med,2003,34(6):774-84. 被引量：1
二级参考文献16
1[2]Rodriguez-Manas L, Angulo J, Peiro C et al. Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br J Pharmacol, 1998;123(8):1495～502 被引量：1
2[3]Tan KC, Chow WS, Ai VH et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care, 2002;25(6):1055～9 被引量：1
3[4]Vlassara H, Fuh H, Makita Z et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals:A model for diabetic and aging complications. Proc Natl Acad Sci USA, 1992;89(24):12043～7 被引量：1
4[5]Angulo J, Sanchez-Ferrer CF, Peiro C et al. Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin:Possible mechanisms involved. Hypertension, 1996;28(4):583～92 被引量：1
5[6]Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest, 1991;87(2):432～8 被引量：1
6[7]Ozyazgan S, Unlucerci Y, Bekpinar S, Akkan AG. Impaired relaxation in aorta from streptozotocin-diabetic rats:Effect of aminoguanidine (AMNG) treatment. Int J Exp Diabetes Res, 2000;1(2):145～53 被引量：1
7[8]Rojas A, Romay S, Gonzalez D et al. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res, 2000;86(3):50～4 被引量：1
8[9]Rumble JR, Cooper ME, Soulis T et al. Vascular hypertrophy in experimental diabetes:Role of advanced glycation end products. J Clin Invest, 1997;99(5):1016～27 被引量：1
9[10]Ihm SH, Yoo HJ, Park SW et al. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism, 1999;48(9):1141～5 被引量：1
10[11]Kedziora-Kornatowska KZ, Luciak M, Blaszczyk J et al. Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Clin Chem Lab Med, 1998;36(10):771～5 被引量：1
